NervGen Pharma Corp.
NGENF
$2.17
$0.01820.85%
OTC PK
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -22.66% | 27.31% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -7.34% | 19.66% | |||
| Operating Income | 7.34% | -19.66% | |||
| Income Before Tax | -60.51% | 33.01% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -60.51% | 33.01% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -60.51% | 33.01% | |||
| EBIT | 7.34% | -19.66% | |||
| EBITDA | 7.37% | -19.71% | |||
| EPS Basic | -60.69% | 33.13% | |||
| Normalized Basic EPS | -60.53% | 33.07% | |||
| EPS Diluted | -60.69% | 33.13% | |||
| Normalized Diluted EPS | -60.53% | 33.07% | |||
| Average Basic Shares Outstanding | -0.12% | 0.17% | |||
| Average Diluted Shares Outstanding | -0.12% | 0.17% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||